Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

OBJECTIVE: To determine if the dipeptidyl peptidase-4 inhibitor vildagliptin more effectively inhibits glucagon levels than the sulfonylurea glimepiride during a meal. RESEARCH DESIGN AND METHODS: Glucagon responses to a standard meal were measured at baseline and study end point (mean 1.8 years) in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ahrén, Bo, Foley, James E., Ferrannini, Ele, Matthews, David R., Zinman, Bernard, Dejager, Sylvie, Fonseca, Vivian A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Diabetes Association 2010
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2845014/
https://ncbi.nlm.nih.gov/pubmed/20067974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc09-1867
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados